Recover leverages data, technology, and novel clinical protocols to provide best-in-class treatment with methods shown to be effective for over 70% of patients. The platform provides medication, care coordination and counseling integrated into comprehensive addiction treatment. By partnering directly with government entities, Recover positions itself as a cost-effective, scalable solution to a fragmented addiction treatment market.
Cyborg Score Rationale
Recover demonstrates strong clinical efficacy (70% patient improvement rate), proven government partnerships, Y Combinator backing, and a clear B2G go-to-market strategy in a high-need market. Early-stage data limitations and limited revenue disclosure prevent a higher score.
Top Insights
Clinical efficacy differentiated: 70% patient improvement rate vs. 8% for conventional programs, with 80% overdose reduction claims
B2G moat: Direct government partnerships reduce customer acquisition friction and create sticky, high-value contracts in underserved markets
Medication-first model: Integration of medication-assisted treatment (MAT) with telehealth removes geographic and stigma barriers endemic to traditional addiction treatment
Early-stage capital efficiency: Seed-funded with Y Combinator backing; minimal disclosed funding suggests lean unit economics focus
Named Competitors
Ro — Telehealth platform offering addiction and mental health treatment
Mindbloom — Ketamine-assisted therapy and behavioral health via telehealth
Teladoc Health — Virtual care platform including behavioral health services
SAMHSA-Certified Programs — Government-run and nonprofit addiction treatment facilities
Recent Developments
(March 2026) Active venture capital backing with Springbank Collective and Y Combinator investors
Open the full interactive Recover report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.